Crossroads by Alantra

Interoperability has been a major topic in Digital Health for over a decade, but initial progress was slow and enabling technologies have only taken off in the last few years.

Joe Gagnon, CEO of 1upHealth, a fast-growing data interoperability vendor, joins Alantra for a discussion on its evolution, namely the FHIR standard, how payers and ACOs are acting as agents of change, the potential for collaboration among Digital Health vendors, and how interoperability platforms could evolve over time into ecosystems.

Matthew Appleton, Partner at Allen & Overy, joins Rusty Ray and Chris Harley-Martin of Alantra for a discussion on key legal considerations when transacting in consumer health. The three discuss the move of consumer health towards FMCG, the growth in legal complexity of brands and platforms, the level of diligence that buyers conduct today, the particularly new focus areas around personal data and supply chains, regulatory interventions, and the early collaboration and education needed between commercial and legal teams.

A banker, consultant, and operator who have each have spent decades in Consumer Health discuss what has driven private equity’s emergence in the space and their perspectives on how investors think about brand or platform opportunities.

Presented by Rusty Ray, Managing Partner at Alantra, Charles Tillen, Partner at Bain & Company, and Chris Harley-Martin, Former Global Head of Business Development for GSK Consumer Health.

Chris Harley-Martin, former Global Head of Business Development at GSK Consumer Health and now Senior Advisor with Alantra, continues off from his previous conversation with how sellers think about evaluating divestitures, regional differences in consumer health between the US and EU, and asset-light platform models with the emergence of third-party vendors to manage the “blocking and tackling” while management focuses on strategy.

Chris Harley-Martin, former Global Head of Business Development at GSK Consumer Health and now Senior Advisor with Alantra, brings his perspective from his 30 years in consumer health. Chris walks us through how he has seen the sector evolve over his career, including the recent emergence of private equity-backed platforms and how major players are thinking about their acquisition and divestment priorities today.

Richard Resnick, CEO of Cureatr and former CEO of GQ Life Sciences, acquired by Aptean, explains his perspectives on human error in care delivery and how it spurred the idea for his latest company, Cureatr, that offers tech-enabled medication management to reduce readmissions into hospitals. He also describes the challenges unique to selling software into health systems and his thoughts on value-based care.

Misti Ushio, former CEO of TARA Biosystems acquired by Valo Health, explains the genesis of her lab-engineered, mature, functioning human heart tissue company, why pharma R&D teams need access to biology-in-a-dish and the data it can generate, and how she sees the future of the organ-on-a-chip space.

Learn more about TARA's acquisition by Valo Health at https://www.alantra.com/ib-transaction/tara-sell-side-advisory-valo-health/